Politician trade (Senate)

Eli Lilly (LLY): Sen. Shelley Moore Capito disclosed a purchase $1K–$15K

Sen. Shelley Moore Capito disclosed a purchase of Eli Lilly in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
11 days
Disclosure lag
Traded
Oct 24, 2025
Disclosed
Nov 4, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 29, 2024CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  2. Apr 23, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  3. May 6, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  4. May 21, 2025CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  5. Aug 11, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  6. Aug 14, 2025Congress · 2 peopleMembers of Congress: 2 purchases, 1 sale
  7. Aug 22, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  8. Aug 28, 2025InsiderOfficer sold ~$735K of LLY shares in the open market
  9. Sep 18, 2025Insider · 1 personInsiders: 5 sales (~$81.5M)
  10. Sep 19, 2025Insider · 1 personInsiders: 2 sales (~$18.1M)
  11. Sep 25, 2025FDAFDA drug approval: Inluriyo
  12. Oct 1, 2025Insider · 1 personInsiders: 55 sales (~$284.7M)
  13. Oct 2, 2025Insider · 1 personInsiders: 8 sales (~$91.4M)

What came next

  1. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  2. Oct 30, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 8.6%
  3. Oct 30, 20255% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 10.1%
  4. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025.”
  5. Nov 20, 2025FDAFDA drug approval: Retevmo
  6. Nov 20, 2025FDAFDA drug approval: Retevmo
  7. Dec 19, 2025FDAFDA drug approval: Mounjaro
  8. Jan 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.8%
  9. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSenate eFD periodic transaction report

How to read Senate eFD periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Sen. Shelley Moore Capito

The full history of Sen. Shelley Moore Capito is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded Eli Lilly (LLY) stock, and how much?

Sen. Shelley Moore Capito disclosed a purchase of Eli Lilly in the $1K–$15K range. Reported range, not an exact amount, Spouse account.

When did it happen, and when was it made public?

Traded: Oct 24, 2025. Disclosed: Nov 4, 2025. That is 11 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the Senate eFD periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Eli Lilly recently?

For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days. They are listed on the LLY page.

Does this mean LLY stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data